IGM Biosciences Inc Ordinary Shares IGMS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IGMS is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $9.27
- Day Range
- $9.20–9.71
- 52-Week Range
- $3.81–17.78
- Bid/Ask
- $10.26 / $10.88
- Market Cap
- $567.29 Mil
- Volume/Avg
- 244,280 / 304,086
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 237.00
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 224
- Website
- https://www.igmbio.com
Comparables
Valuation
Metric
|
IGMS
|
MRSN
|
CLDX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.79 | 14.65 | 5.45 |
Price/Sales | 237.00 | 14.11 | 294.86 |
Price/Cash Flow | — | — | — |
Price/Earnings
IGMS
MRSN
CLDX
Financial Strength
Metric
|
IGMS
|
MRSN
|
CLDX
|
---|---|---|---|
Quick Ratio | 7.95 | 3.29 | 13.69 |
Current Ratio | 8.18 | 3.36 | 13.87 |
Interest Coverage | — | −44.11 | — |
Quick Ratio
IGMS
MRSN
CLDX
Profitability
Metric
|
IGMS
|
MRSN
|
CLDX
|
---|---|---|---|
Return on Assets (Normalized) | −44.52% | −49.57% | −30.49% |
Return on Equity (Normalized) | −84.37% | −211.52% | −33.19% |
Return on Invested Capital (Normalized) | −77.23% | −146.81% | −32.85% |
Return on Assets
IGMS
MRSN
CLDX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fclysprbfn | Ljtqt | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qsvwntr | Qyrbww | $108.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fywxwrbd | Gnqdp | $105.6 Bil | |
MRNA
| Moderna Inc | Vmqhbcmb | Mpqsq | $40.8 Bil | |
ARGX
| argenx SE ADR | Zzxcktnq | Dzzf | $23.7 Bil | |
BNTX
| BioNTech SE ADR | Sghznbrw | Jpnmp | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hsjvvxkq | Fqrth | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ybwkfbm | Qzwcbs | $16.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bmxngwjkd | Kwdbrvn | $13.6 Bil | |
INCY
| Incyte Corp | Mjczgpyt | Hsjxs | $12.8 Bil |